KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Invested Capital: 2020-2025

Historic Invested Capital for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $1.1 billion.

  • Recursion Pharmaceuticals' Invested Capital rose 98.18% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 98.18%. This contributed to the annual value of $1.0 billion for FY2024, which is 125.08% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Invested Capital of $1.1 billion as of Q3 2025, which was up 13.79% from $927.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Invested Capital's 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of -$233.0 million in Q1 2021.
  • Moreover, its 3-year median value for Invested Capital was $532.8 million (2024), whereas its average is $663.3 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Invested Capital soared by 363.19% in 2021, and later tumbled by 35.22% in 2022.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Invested Capital stood at $542.9 million in 2021, then fell by 10.52% to $485.8 million in 2022, then declined by 4.60% to $463.5 million in 2023, then soared by 125.08% to $1.0 billion in 2024, then skyrocketed by 98.18% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $927.9 million for Q2 2025 and $942.5 million for Q1 2025.